Tag Archives: Dewey Steadman

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aerie Pharma (NASDAQ: AERI), SCYNEXIS (NASDAQ: SCYX) and Intercept Pharma (NASDAQ: ICPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (NASDAQ: AERI), SCYNEXIS (NASDAQ: SCYX) and Intercept Pharma (NASDAQ: ICPT). Aerie Pharma (NASDAQ: AERI) Canaccord Genuity analyst Dewey Steadman maintained a Buy rating

KemPharm Gets a Buy Rating from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on KemPharm (NASDAQ: KMPH) today and set a price target of $11. The company’s shares opened today at $5.30. Steadman commented: “We are encouraged by KemPharm’s progress with the ADHD program,

Analysts’ Top Healthcare Picks: SVRA, PTLA

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara Inc (NASDAQ: SVRA), Portola Pharma (NASDAQ: PTLA) and Ultragenyx (NASDAQ: RARE) with bullish sentiments. Savara Inc (NASDAQ: SVRA) Canaccord Genuity analyst

Aceto Corp Gets a Sell Rating from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Sell rating on Aceto Corp (NASDAQ: ACET) today and set a price target of $2. The company’s shares opened today at $2.83, close to its 52-week low of $2.22. According to TipRanks.com, Steadman

Pacira Pharmaceuticals Gets a Hold Rating from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $34. The company’s shares opened today at $33.05. According to TipRanks.com, Steadman is ranked 0 out of 5 stars

Pacira Pharmaceuticals Receives a Hold from Canaccord Genuity

In a report released yesterday, Dewey Steadman from Canaccord Genuity reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $34. The company’s shares closed on Friday at $33.30. According to TipRanks.com, Steadman is ranked 0